Derek J. Hoelz

Founder at CS-Keys, Inc.

Health Technology

Consumer Services

Profile

Derek J.
Hoelz is a Co-Founder of CS-Keys, Inc. and a Research Assistant Professor at the Indiana University School of Medicine.
He has research experience in mass spectrometry, molecular biology, enzymatic assays, protein chemistry, and scientific computer software.
Dr. Hoelz holds a PhD degree.

Derek J. Hoelz active positions

Companies	Position	Start
CS-Keys, Inc. CS-Keys, Inc. Medical SpecialtiesHealth Technology CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University.	Founder	2009-08-04
Indiana University	Corporate Officer/Principal	-

All active positions of Derek J. Hoelz

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Derek J. Hoelz's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
CS-Keys, Inc. CS-Keys, Inc. Medical SpecialtiesHealth Technology CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University.	Health Technology